November 15, 2024

PHABIOC GmbH Launches Series Production of the Revolutionary SpecPlate for Pharmaceutical and Biotech Research

PHABIOC GmbH Launches Series Production of the Revolutionary SpecPlate for Pharmaceutical and Biotech Research

A new level of efficiency, precision and sustainability in UV/Vis spectroscopy

PHABIOC GmbH announces the start of mass production of its innovative SpecPlate – a multiwell plate designed specifically for the needs of pharmaceutical and biotech research. The SpecPlate sets new standards in plate-based UV/Vis spectroscopy by improving efficiency and precision while significantly reducing material consumption. This makes laboratory processes more effective and sustainable.

Technological innovation for more accurate results 

The SpecPlate features closed, stepped measurement chambers that allow measurements over a wide range of concentrations without the need for dilution. With a sample volume of only 36 µL, the measurement chambers provide a defined path length and eliminate the influence of liquid menisci or pipetting inaccuracies on the measurement result. Compatibility with popular plate readers and automated pipetting systems is particularly advantageous: The inlets of the measurement structures are arranged in the grid of a standard 96-well plate, while the measurement chambers are arranged in the grid of a 384-well plate. This allows the SpecPlate to be seamlessly integrated into established laboratory systems and processes. 

“The SpecPlate addresses the errors and limitations of the gold standard and combines its advantages. The SpecPlate is the better standard,” says Dr. Carsten Radtke, co-inventor of the SpecPlate and CSO of PHABIOC GmbH.

Sustainability and efficiency in a single product 

In comparative tests, the SpecPlate impressed not only with its precision, but also with considerable savings: 75% less laboratory consumables and a two-thirds reduction in process time. This increase in efficiency makes the SpecPlate particularly attractive to laboratories that value fast, cost-effective and sustainable processes.

Developed from cutting-edge research and collaborative partnerships

The SpecPlate was originally developed at the Karlsruhe Institute of Technology (KIT) in the research group of Prof. Jürgen Hubbuch. Together with industry partners, the SpecPlate was brought to market. PHABIOC is pleased to have found a manufacturing partner in Germany that offers short delivery and communication channels as well as the highest product quality.

Early customer feedback confirms the benefits of SpecPlate 

The SpecPlate has already received positive feedback from pilot customers, including some of the leading pharmaceutical companies:

“The integration of SpecPlate promises to significantly speed up and simplify our processes by reducing the number of steps required and enabling us to obtain more data points from the sample measurements. “*

Another customer praises the compatibility: “The use in already established instruments offers a low integration threshold into our existing workflows”.

Contact:

Dr.-Ing. Carsten Radtke 
PHABIOC GmbH 
E-mail: carsten.radtke@phabioc.com 
Fon: +49 123 45678 
Website: http://www.phabioc.com

Our latest News

discover more
Workflow Optimisation in the Laboratory: Premiere of the smartLabs Summit in Heidelberg

Workflow Optimisation in the Laboratory: Premiere of the smartLabs Summit in Heidelberg

On September 24, 2025, the smartLabs Summit will open its doors for the first time in Heidelberg – an event dedicated to practical innovation, digitalization, and automation in laboratories. The Summit will take place at BioLabs Heidelberg (Nicola-Tesla Straße 1–3, 69124 Heidelberg) and offers a full program from 1:00 to 7:30 p.m. Initiated by the […]

DFG awards Heidelberg research project on early detection of spinal degeneration nearly €250,000 in funding

DFG awards Heidelberg research project on early detection of spinal degeneration nearly €250,000 in funding

The aim of the project is to use special quantitative MRI to visualize early changes in the intervertebral disc and enable timely treatment. Ultrashort echo time (UTE) MRI opens up completely new approaches to preventive imaging that are difficult or impossible to achieve with conventional MRI methods. Full text in German below. DFG fördert Heidelberger […]

Glioblastoma study shows: Molecular diagnostics could enable targeted therapies without delay

Glioblastoma study shows: Molecular diagnostics could enable targeted therapies without delay

Researchers from Heidelberg University’s Medical Faculty, the German Cancer Research Center (DKFZ), and the National Center for Tumor Diseases (NCT) in Heidelberg have tested the use of targeted drugs in the initial treatment of newly diagnosed glioblastoma, an extremely aggressive brain tumor, in the multicenter study “NCT Neuro Master Match (N2M2)”. Of the five drugs […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp